REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $785.84 million. The enterprise value is $597.85 million.
| Market Cap | 785.84M |
| Enterprise Value | 597.85M |
Important Dates
The next estimated earnings date is Wednesday, May 1, 2024, after market close.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 48.99 million shares outstanding. The number of shares has increased by 1.35% in one year.
| Shares Outstanding | 48.99M |
| Shares Change (YoY) | +1.35% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 7.18% |
| Owned by Institutions (%) | 81.71% |
| Float | 37.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.71 |
| Forward PS | 6.53 |
| PB Ratio | 2.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.57 |
| Quick Ratio | 2.32 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.42 |
Financial Efficiency
Return on equity (ROE) is -68.20% and return on invested capital (ROIC) is -66.86%.
| Return on Equity (ROE) | -68.20% |
| Return on Assets (ROA) | -40.00% |
| Return on Capital (ROIC) | -66.86% |
| Revenue Per Employee | $262,331 |
| Profits Per Employee | -$765,971 |
| Employee Count | 344 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -152,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.28% in the last 52 weeks. The beta is 1.32, so REGENXBIO's price volatility has been higher than the market average.
| Beta (1Y) | 1.32 |
| 52-Week Price Change | -16.28% |
| 50-Day Moving Average | 19.83 |
| 200-Day Moving Average | 17.83 |
| Relative Strength Index (RSI) | 28.99 |
| Average Volume (30 Days) | 747,301 |
Short Selling Information
The latest short interest is 3.95 million, so 8.05% of the outstanding shares have been sold short.
| Short Interest | 3.95M |
| Short Previous Month | 4.15M |
| Short % of Shares Out | 8.05% |
| Short % of Float | 10.56% |
| Short Ratio (days to cover) | 4.06 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $90.24 million and -$263.49 million in losses. Loss per share was -$6.02.
| Revenue | 90.24M |
| Gross Profit | 53.03M |
| Operating Income | -268.13M |
| Pretax Income | -263.65M |
| Net Income | -263.49M |
| EBITDA | -239.46M |
| EBIT | -256.78M |
| Loss Per Share | -$6.02 |
Balance Sheet
The company has $277.29 million in cash and $89.29 million in debt, giving a net cash position of $188.00 million or $3.84 per share.
| Cash & Cash Equivalents | 277.29M |
| Total Debt | 89.29M |
| Net Cash | 188.00M |
| Net Cash Per Share | $3.84 |
| Equity / Book Value | 311.74M |
| Book Value Per Share | 6.36 |
| Working Capital | 204.70M |
Cash Flow
In the last 12 months, operating cash flow was -$218.41 million and capital expenditures -$9.96 million, giving a free cash flow of -$228.37 million.
| Operating Cash Flow | -218.41M |
| Capital Expenditures | -9.96M |
| Free Cash Flow | -228.37M |
| FCF Per Share | -$5.22 |
Margins
Gross margin is 58.76%, with operating and profit margins of -297.12% and -291.99%.
| Gross Margin | 58.76% |
| Operating Margin | -297.12% |
| Pretax Margin | -292.15% |
| Profit Margin | -291.99% |
| EBITDA Margin | -265.36% |
| EBIT Margin | -284.55% |
| FCF Margin | -253.06% |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.35% |
| Shareholder Yield | -1.35% |
| Earnings Yield | -33.53% |
| FCF Yield | -29.06% |
Analyst Forecast
The average price target for REGENXBIO is $40.56, which is 152.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.56 |
| Price Target Difference | 152.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 40.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -0.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.81 |
| Piotroski F-Score | 4 |